WINNIPEG, MANITOBA--(Marketwire - February 13, 2008) - Kane Biotech Inc. (TSX VENTURE: KNE) - A biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce a research publication on its PS/CHX technology. PS/CHX, one of the Company’s lead antimicrobial compositions, is a patent pending combination of Chlorhexidine and Protamine Sulfate. The paper appeared in the recent online edition of the Journal of Antimicrobial Chemotherapy (doi:10.1093/jac/dkn006; Impact Factor: 3.9).
